NGM Biopharmaceuticals, Inc.
(NASDAQ GS: NGM)
Rigrodsky Law, P.A. is investigating NGM Biopharmaceuticals, Inc. (“NGM”) regarding possible breaches of fiduciary duties and other violations of law related to NGM’s agreement to be acquired by affiliates of The Column Group, LP. Under the terms of the agreement, NGM shareholders will receive $ 1.55 per share in cash.